Digital repository of Slovenian research organisations

Show document
A+ | A- | Help | SLO | ENG

Title:Treatment outcomes and relative dose intensity of chemotherapy in patients with advanced Hodgkin lymphoma
Authors:ID Rožman, Samo (Author)
ID Jezeršek Novaković, Barbara (Author)
ID Ružić Gorenjec, Nina (Author)
ID Novaković, Srdjan (Author)
Files:.pdf PDF - Presentation file, download (794,55 KB)
MD5: A18205F1484753CF9F49F5874A13DECA
 
Language:English
Typology:1.01 - Original Scientific Article
Organization:Logo OI - Institute of Oncology
Abstract:The present retrospective study was undertaken to investigate the association of relative dose intensity (RDI) with the outcome of patients with advanced stage Hodgkin lymphoma (HL) receiving ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) and escalated BEACOPP regimens (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone). A total of 114 patients with HL treated between 2004 and 2013 were enrolled for evaluation. The association of variables with overall survival (OS) and progression-free survival (PFS) was analysed using univariate and multivariate Cox proportional hazards models. The median age of patients was 39 years, and the majority were male and had stage IV disease. A total of 54 patients received ABVD and 60 received BEACOPP chemotherapy with 24 and four deaths, respectively. Patients in the BEACOPP group were significantly younger with lower Charlson comorbidity index (CCI) and better performance status in comparison with the ABVD group, making the comparison of groups not possible. In the ABVD group, RDI was not significantly associated with OS (P=0.590) or PFS (P=0.354) in a multivariate model where age was controlled. The low number of events prevented this analysis in the BEACOPP group. The age of patients was strongly associated with both OS and PFS; all statistically significant predictors for OS and PFS from univariate analyses (chemotherapy regimen, CCI, RDI, performance status) lost their effect in multivariate analyses where age was controlled. Based on these observations, it was concluded that RDI was not associated with OS or PFS after age is controlled, neither in all patients combined nor in the ABVD group.
Keywords:Hodgkin lymphoma, chemotherapy, outcome, primary treatment
Publication status:Published
Publication version:Version of Record
Publication date:19.07.2022
Publisher:Spandidos
Year of publishing:2022
Number of pages:str. 320-1-320-7
Numbering:Vol. 24, no. 3
PID:20.500.12556/DiRROS-15586 New window
UDC:616.1/.4
ISSN on article:1792-1074
DOI:10.3892/ol.2022.13440 New window
COBISS.SI-ID:118357251 New window
Copyright:by Authors
Publication date in DiRROS:23.09.2022
Views:498
Downloads:151
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
  
Share:Bookmark and Share


Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:Oncology Letters
Shortened title:Oncol. Lett.
Publisher:Ekdoseis A. Spantidos
ISSN:1792-1074
COBISS.SI-ID:28632281 New window

Document is financed by a project

Funder:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Project number:P3-0321-2020
Name:Napovedni dejavniki poteka bolezni in odgovora na zdravljenje pri različnih vrst raka

Licences

License:CC BY-NC-ND 4.0, Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Link:http://creativecommons.org/licenses/by-nc-nd/4.0/
Description:The most restrictive Creative Commons license. This only allows people to download and share the work for no commercial gain and for no other purposes.
Licensing start date:23.09.2022

Secondary language

Language:Slovenian
Keywords:Hodgkinov limfom, kemoterapija, neželeni učinki, osnovno zdravljenje


Back